Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Jun 20 04:00PM ET
1.04
Dollar change
0.00
Percentage change
0.00
%
IndexRUT P/E- EPS (ttm)-2.96 Insider Own33.25% Shs Outstand22.30M Perf Week-4.59%
Market Cap23.28M Forward P/E- EPS next Y-2.49 Insider Trans0.00% Shs Float14.94M Perf Month-37.35%
Income-65.69M PEG- EPS next Q-0.73 Inst Own52.75% Short Float3.23% Perf Quarter-33.76%
Sales0.00M P/S- EPS this Y34.72% Inst Trans0.65% Short Ratio4.68 Perf Half Y-58.57%
Book/sh6.13 P/B0.17 EPS next Y0.93% ROA-42.61% Short Interest0.48M Perf Year-83.14%
Cash/sh6.18 P/C0.17 EPS next 5Y24.30% ROE-54.06% 52W Range1.01 - 6.24 Perf YTD-64.14%
Dividend Est.- P/FCF- EPS past 5Y- ROIC-35.53% 52W High-83.33% Beta-0.79
Dividend TTM- Quick Ratio22.15 Sales past 5Y- Gross Margin- 52W Low2.97% ATR (14)0.10
Dividend Ex-Date- Current Ratio22.15 EPS Y/Y TTM- Oper. Margin- RSI (14)33.99 Volatility3.09% 4.98%
Employees64 Debt/Eq0.36 Sales Y/Y TTM- Profit Margin- Recom2.33 Target Price4.00
Option/ShortNo / Yes LT Debt/Eq0.35 EPS Q/Q-1.92% Payout- Rel Volume2.07 Prev Close1.04
Sales Surprise- EPS Surprise3.40% Sales Q/Q- EarningsMay 09 BMO Avg Volume103.10K Price1.04
SMA20-10.50% SMA50-23.73% SMA200-54.45% Trades Volume213,385 Change0.00%
Date Action Analyst Rating Change Price Target Change
Jun-02-25Initiated H.C. Wainwright Buy $5
May-28-25Downgrade Leerink Partners Outperform → Market Perform $3
Dec-13-24Downgrade Guggenheim Buy → Neutral
Apr-22-24Initiated Piper Sandler Overweight $20
Apr-22-24Initiated Leerink Partners Outperform $25
Apr-22-24Initiated Guggenheim Buy $24
Jun-05-25 04:58PM
May-23-25 04:01PM
May-14-25 12:00PM
May-09-25 07:00AM
May-01-25 08:23AM
07:00AM Loading…
Apr-03-25 07:00AM
Mar-27-25 07:00AM
Feb-26-25 07:00AM
Feb-03-25 10:00AM
Dec-12-24 04:01PM
Nov-25-24 07:00AM
Nov-07-24 04:01PM
Nov-05-24 07:00AM
Oct-14-24 08:00AM
Sep-11-24 07:00AM
04:28AM Loading…
Aug-13-24 04:28AM
03:32AM
Aug-12-24 10:53PM
04:01PM
Jun-05-24 07:00AM
May-13-24 02:53PM
07:00AM
May-06-24 08:00AM
May-01-24 10:05AM
Apr-14-24 11:37AM
Apr-11-24 08:00AM
Apr-08-24 08:00AM
Mar-27-24 06:55PM
Boundless Bio, Inc. is a clinical-stage oncology company, which is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the significant unmet need in patients with oncogene amplified tumors by targeting extrachromosomal DNA. The company was founded by Vineet Bafna, Paul Mischel, Benjamin F. Cravatt, and Jonathan E. Lim on April 10, 2018 and is headquartered in San Diego, CA.